According to research published in JACC: Heart Failure, patients with heart failure who experience low health literacy are at an increased risk of hospitalisation and mortality. A press release reports that this finding has significant clinical and public health implications and suggests that assessing and intervening upon an individual’s understanding of their own health could improve heart failure outcomes.

According to research published in JACC: Heart Failure, patients with heart failure who experience low health literacy are at an increased risk of hospitalisation and mortality. A press release reports that this finding has significant clinical and public health implications and suggests that assessing and intervening upon an individual’s understanding of their own health could improve heart failure outcomes.

Data from more than 1,000 patients presented during the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrates Impella (Abiomed) reduced in-hospital mortality when placed before a non-emergent percutaneous coronary intervention (PCI) is performed. According to a press release, the research found that, in the setting of high-risk PCI, when Impella is placed pre-PCI, it is associated with a 10 times reduction of in-hospital mortality, compared to when Impella is placed during “bailout” PCI.

Edwards Lifesciences has received the CE mark for the PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.

A late-breaking clinical trial presented at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrated strong long-term haemodynamic and safety outcomes for the Melody transcatheter pulmonary valve (Medtronic). Additionally, results from a second late-breaking trial—for the investigational Harmony transcatheter pulmonary valve (also Medtronic)—met its safety and efficacy endpoints for haemodynamic function at six months

A late-breaking clinical trial presented at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrated strong long-term haemodynamic and safety outcomes for the Melody transcatheter pulmonary valve (Medtronic). Additionally, results from a second late-breaking trial—for the investigational Harmony transcatheter pulmonary valve (also Medtronic)—met its safety and efficacy endpoints for haemodynamic function at six months.

A study presented yesterday at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) indicates that the addition of icosapent ethyl to statin therapy in patients with elevated triglycerides and increased cardiovascular risk is associated with reductions in first and repeat revascularisations.

The Society for Cardiovascular Angiography and Interventions (SCAI)has published a position statement addressing optimal percutaneous coronary intervention (PCI) treatment of patients with complex coronary artery disease. The position statement was presented today during the SCAI 2020 Scientific Sessions Virtual Conference and published in SCAI’s official journal, Catheterization and Cardiovascular Interventions.

The American College of Cardiology (ACC) is start to collecting COVID-19 data through the NCDR Chest Pain-MI and CathPCI registries with the aim of capturing the relationship between COVID-19 and heart disease and maximise data on the cardiac impact of the virus. A press release reports that hospitals already participating in these registries will have the first opportunity to add to the world’s growing knowledge on the impact of the virus on cardiovascular disease and engage in the global conversation on best patient care in the pandemic.

A joint UK-US research team is applying an artificial intelligence (AI) system to map for the first time how the COVID-19 virus attacks the heart with such deadly impact. This week, British health-tech company Ultromics and Mayo Clinic in the USA will use AI software, EchoGo Core, to analyse echocardiograms of COVID-19 patients, for clues about how the virus affects the human cardiovascular system.

Corresponding author Valentin Fuster (Mount Sinai Heart, New York, USA) and colleagues report in the Journal of the American College of Cardiology that hospitalised COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting. They add their work outlines an important therapeutic pathway for COVID-19 patients.